目的:检测parafibromin蛋白在人颌骨骨肉瘤(osteosarcoma of the jaws,JOS)中的表达情况,探讨其在JOS的发生、发展中的作用。方法:采用免疫组织化学的方法检测parafibromin蛋白在47例JOS和11例颌骨骨化纤维瘤(ossifying fibroma of the ...目的:检测parafibromin蛋白在人颌骨骨肉瘤(osteosarcoma of the jaws,JOS)中的表达情况,探讨其在JOS的发生、发展中的作用。方法:采用免疫组织化学的方法检测parafibromin蛋白在47例JOS和11例颌骨骨化纤维瘤(ossifying fibroma of the jaws,JOF)中的表达情况。结果:JOS中,parafibromin高表达、中等表达、低表达患者分别占48.9%(23/47)、40.4%(19/47)和10.7%(5/47);JOF中,三者所占的百分率分别为90.9%(10/11)、9.1%(1/11)和0.0%(0),与JOS相比,差异有统计学意义(U=147.5,P=0.012);parafibromin在高分化型JOS中的表达水平高于传统型JOS(U=71.0,P=0.021);parafibromin的表达情况与临床病理参数间无相关性(P>0.05)。结论:parafibromin蛋白在JOS中表达下调,这种表达的减少可能与JOS的分化和恶性程度有关。展开更多
Background It is widely recognized that the diagnosis of parathyroid carcinoma （PC） is often difficult because of the overlap of characteristics between malignant and benign parathyroid tumors, especially at an earl...Background It is widely recognized that the diagnosis of parathyroid carcinoma （PC） is often difficult because of the overlap of characteristics between malignant and benign parathyroid tumors, especially at an early stage. Our study aimed to investigate the differential expression of Ki-67, galectin-3, fragile histidine triad （FHIT） gene, and parafibromin in PC, parathyroid adenoma （PA）, parathyroid hyperplasia （PH）, and normal parathyroid （NP） tissues; then to assess these expression values for use in differential diagnosis of malignant and benign parathyroid tumors. Methods Data of 15 cases with PC, 19 PAs, and 8 PHs were retrospectively analyzed for their clinical characteristics. The expression of Ki-67, galectin-3, FHIT, and parafibromin were detected via immunohistochemistry in the above-mentioned specimens and 6 NPs as control. Results Complete loss of parafibromin expression was seen in 9 of 15 （60%） carcinomas, and all normal parathyroid tissues and parathyroid benign tumors stained positive for parafibromin except for one （4%） adenoma. Galectin-3 staining was positive in 11 of 15 （73%） carcinomas, 5 of 19 （26%） adenomas, 1 of 8 （12%） hyperplasias, and 0 of 6 normal tissues. The Ki-67 proliferative index was high in 4 of 15 （27%） carcinomas, 1 of 19 （5%） adenomas, and none of the hyperplasia or normal tissues. FHIT expression did not differ appreciably among the tumor types. The combination of overexpression of galectin-3 or loss of parafibromin increased sensitivity for PC to 87%, while the specificity of both positive galectin-3 and positive Ki-67 could reach 100%. Conclusions These data suggested that loss of parafibromin and overexpression of galectin-3 and Ki-67 might help to distinguish parathyroid carcinoma from other parathyroid tumors. And the combination of two or three of these markers might produce better sensitivity and/or specificity for the diagnosis of parathyroid carcinoma.展开更多
文摘目的:检测parafibromin蛋白在人颌骨骨肉瘤(osteosarcoma of the jaws,JOS)中的表达情况,探讨其在JOS的发生、发展中的作用。方法:采用免疫组织化学的方法检测parafibromin蛋白在47例JOS和11例颌骨骨化纤维瘤(ossifying fibroma of the jaws,JOF)中的表达情况。结果:JOS中,parafibromin高表达、中等表达、低表达患者分别占48.9%(23/47)、40.4%(19/47)和10.7%(5/47);JOF中,三者所占的百分率分别为90.9%(10/11)、9.1%(1/11)和0.0%(0),与JOS相比,差异有统计学意义(U=147.5,P=0.012);parafibromin在高分化型JOS中的表达水平高于传统型JOS(U=71.0,P=0.021);parafibromin的表达情况与临床病理参数间无相关性(P>0.05)。结论:parafibromin蛋白在JOS中表达下调,这种表达的减少可能与JOS的分化和恶性程度有关。
基金WANG Ou and WANG Chun-yan contributed equally to this work. This work was partly supported by the grant from the Project of National Natural Science Foundation of China （No. 81100559）. Conflict of interests： The authors declare that they have no conflict of interests.
文摘Background It is widely recognized that the diagnosis of parathyroid carcinoma （PC） is often difficult because of the overlap of characteristics between malignant and benign parathyroid tumors, especially at an early stage. Our study aimed to investigate the differential expression of Ki-67, galectin-3, fragile histidine triad （FHIT） gene, and parafibromin in PC, parathyroid adenoma （PA）, parathyroid hyperplasia （PH）, and normal parathyroid （NP） tissues; then to assess these expression values for use in differential diagnosis of malignant and benign parathyroid tumors. Methods Data of 15 cases with PC, 19 PAs, and 8 PHs were retrospectively analyzed for their clinical characteristics. The expression of Ki-67, galectin-3, FHIT, and parafibromin were detected via immunohistochemistry in the above-mentioned specimens and 6 NPs as control. Results Complete loss of parafibromin expression was seen in 9 of 15 （60%） carcinomas, and all normal parathyroid tissues and parathyroid benign tumors stained positive for parafibromin except for one （4%） adenoma. Galectin-3 staining was positive in 11 of 15 （73%） carcinomas, 5 of 19 （26%） adenomas, 1 of 8 （12%） hyperplasias, and 0 of 6 normal tissues. The Ki-67 proliferative index was high in 4 of 15 （27%） carcinomas, 1 of 19 （5%） adenomas, and none of the hyperplasia or normal tissues. FHIT expression did not differ appreciably among the tumor types. The combination of overexpression of galectin-3 or loss of parafibromin increased sensitivity for PC to 87%, while the specificity of both positive galectin-3 and positive Ki-67 could reach 100%. Conclusions These data suggested that loss of parafibromin and overexpression of galectin-3 and Ki-67 might help to distinguish parathyroid carcinoma from other parathyroid tumors. And the combination of two or three of these markers might produce better sensitivity and/or specificity for the diagnosis of parathyroid carcinoma.
